soul trial oral semaglutide cardiovascular outcomes 2024 results nejm and in... : New England Journal of Medicine The SOUL trial (Semaglutide Cardiovascular – Oral Semaglutide Cuts Cardiovascular Risk

Treatment with semaglutide reduces risk of death or morbidity from cardiovascular disease- in the SUSTAIN 6 trial (104 weeks, 3297 patients with diabetes and high cardiovascular risk), the risk of developing cardiovascular death, myocardial infarction (heart attack) or stroke was reduced by 26% in the patients treated with semaglutide (Ozempic)

The governors plan is set against the backdrop of a looming $12 billion state budget deficit, requiring significant fiscal adjustments

It is most associated with SGLT2 inhibitors (a different class of diabetes drug) but has been reported with GLP-1 medications in the context of very low carbohydrate intake, particularly during illness, fasting, or periods of very low food intake

Dosage and Administration Both medications are administered once weekly through a subcutaneous injection, but the dosing schedule for each varies